We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Demonstrates Rapid Immunofluorescence Quantitative Analyzers for POC Testing

By LabMedica International staff writers
Posted on 25 Jul 2023

Getein Biotech, Inc. More...

(Nanjing, China) is showcasing its latest innovations at AACC 2023 including its benchtop immunofluorescence and hematology analyzers as well as its handheld POCT analyzers.

At AACC 2023, Getein is demonstrating the Metis 600 integrated system that provides a suitable solution for immunofluorescence and hematology testing to low-volume laboratories. The combination of immunofluorescence and hematology methodologies in a single system allows for more comprehensive test items to be offered. Metis 600 improves laboratory efficiency through the highest level of automation and accelerates turnaround time for high-volume sample testing. Also on display is the MAGICL 6000 chemiluminescence immunoassay analyzer, a compact and innovative system offering an optimal choice for mid to high-workflow laboratories that need a one-step chemiluminescence solution. Highly productive and compact, this instrument enables fully automated operation and provides the fastest testing speed of any device of its size.

In addition, the company is demonstrating the Getein 1160 immunofluorescence quantitative analyzer - a multi-channel POCT analyzer with four incubation channels and one emergency test channel. It also has a constant test environment with 32℃ to ensure more accurate test results, making it ideal for applications in emergency, critical care (ICU, CCU), outpatient, cardiology, inpatient wards, clinical laboratories, etc. Alongside this, the company is demonstrating the Getein 1100 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnostics of laboratory and point-of-care testing. In addition, Getein is showcasing the CM-400 fully automated clinical chemistry analyzer that is intended to quantitatively analyze chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples, offering constant throughput of 400 T/h.

Related Links:
Getein Biotech, Inc. 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
mRNA Extraction Kits
TurboCapture mRNA Kits
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.